Veryan Medical Ltd.
This article was originally published in Start Up
While the incorporation of drugs has radically reduced restenosis in coronary stents, it remains a serious issue in other vascular devices. Veryan Medical Ltd. thinks that the problem lies in the limitations of 2-D cylindrical devices to accommodate the natural, 3-D flow of blood. The company is building devices that replicate the swirling flow of blood through the vasculature. That spiral flow flushes out areas of stagnation and prevent the formation of intimal hyperplasia and restenosis.
You may also be interested in...
Having built a franchise serving cardiac surgeon, Edwards is looking to maintain its market leadership by both expanding into peripherals and embracing interventionalists.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Thirty-eight guidance documents have been posted on the tracker since its last update.
Germany’s Merck KGaA rapidly expanded its life sciences services business to support the manufacture of COVID-19 vaccines during 2020, and also expects cancer and multiple sclerosis products to fuel its sales growth in coming years.